Evidence map›Paper›PMID 39655708›Full record

ArticleJournal of biochemical and molecular toxicology2024

Innovation in CRC Research: Targeting SPACA6P-AS for Progression.

Tianyi Ma, Yinghu Jin, Song Wang, Hanqing Hu, Meng Wang, Guoqing Yan, Qingchao Tang, Rui Huang, Guiyu Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biochemical and molecular toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tianyi MaDepartment of Colorectal Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin, China.ORCID http://orcid.org/0000-0003-2736-7710
Yinghu JinDepartment of Colorectal Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Song WangDepartment of Colorectal Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Hanqing HuDepartment of Colorectal Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Meng WangDepartment of Colorectal Surgery, Zhejiang Cancer Hospital (Affiliated Cancer Hospital of the Chinese Academy of Sciences), Hangzhou, China.
Guoqing YanDepartment of Colorectal Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Qingchao TangDepartment of Colorectal Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Rui HuangDepartment of Colorectal Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Guiyu WangDepartment of Colorectal Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin, China.

Funding

This research was partially funded by the Scientific Research Project of the Heilongjiang Provincial Health and Family Planning Commission (Grant No. 2018249), the Heilongjiang Provincial Higher Education Innovation Fund (Grant No. 31041210019), and the Second Affiliated Hospital of Harbin Medical University standardized training project for resident doctors (Grant No.2020020225).
6 · The paper itself

Abstract

The purpose of this research was to provide light on the functional role that the long noncoding RNA SPACA6P-AS plays in the biology of colorectal cancer (CRC). The presence of elevated SPACA6P-AS expression in colorectal cancer tissues is linked to advanced stages of the disease as well as a decreased overall survival rate. It has been demonstrated through knockdown tests conducted on CRC cell lines that SPACA6P-AS stimulates cell growth in both in vitro and in vivo settings. By acting as a competing endogenous RNA, SPACA6P-AS is able to modulate the levels of miR-339-5p and promote the proliferation of colorectal cancer cells by way of the miR-339-5p/FAM167AFAM167A signaling axis. Based on these findings, SPACA6P-AS is a promising candidate for both a prognostic marker and a therapeutic target in colorectal cancer.

Indexed as

Colorectal NeoplasmsMicroRNAsRNA, Long NoncodingAnimalsCell Line, TumorCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, NudeMicroRNAsRNA, Long Noncodingcolorectal cancerFAM167Along noncoding RNAmiR‐339‐5pprognosisproliferationSPACA6P‐AS

Identifiers

PMID39655708
PMCPMC11629451

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.